How is Epstein-Barr infection treated in X-linked lymphoproliferative (XLP) syndrome?

Updated: Jan 27, 2019
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

If there is evidence of  Epstein-Barr virus (EBV)–driven disease, including hemophagocytic lymphohistiocytosis (HLH), treatment with a monoclonal anti-CD20 antibody (rituximab) can be used to deplete the B cell population harboring the virus. This approach is effective at reducing and often clearing the viremia but risks exacerbating long-term hypogammaglobulinemia. [6, 17]  

Antiviral agents are poorly effective against EBV but acyclovir has been used in some circumstances. [6]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!